Mp51-15 the role of 68ga-psma- and 68ga-dota-rm2 pet/mri in the primary staging of high-risk prostate cancer patients undergoing radical prostatectomy. preliminary results of a prospective, single center study

PET (HR 2.7, p[0.001). When testing interaction with use of MDT in patients with positive PSMA PET, men with positive PSMA PET not receiving MDT had significantly higher risk of CR (HR 3.39; p<0.001), while such risk was higher but with lesser magnitude in men with positive PSMA PET receiving MDT (HR 2.14, p[0.02) compared to patients with negative PSMA PET. At the Cox-derived KM, the 3-year CR-free survival rates were 71 vs 48 vs 19% in patients with negative PSMA PET vs positive PSMA PET receiving MDT vs positive PSMA PET not receiving MDT. CONCLUSIONS: A negative PSMA PET/CT scan at the time of BCR represents a protective factor for further metastases during followup. Notably, in patients with positive spots, MDT significantly improved progression-free survival.